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Differential executive functioning performance
by phase of bipolar disorder
Introduction
The literature on individuals with bipolar disorder
(BD) has converged to show deficits in psychomo-
tor speed, executive function, attention, memory,
and fine motor skills (1, 2). Individuals in the active
states of BD illness generally perform worse than
healthy controls on neuropsychological tasks. The
initial findings focused on the acute states of
bipolar illness, but recent studies have shown that
those in the euthymic state demonstrate persistent
or trait-like cognitive deficits as compared to
healthy controls (3–7). Executive functioning
(EF) impairments, however, are not universally
found among the remitted BD patients in these
studies (8–11), suggesting that EF skills may be
more sensitive to fluctuations by phase of illness in
BD.
There have been a limited number of studies
demonstrating phase of illness effects in BD with
regard to EF (7, 12–14). Small sample sizes or
poorly represented BD groups, as well as the
complexity and the multifactorial nature of the
EF system may account for these differences and
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Objective: This study examined the influence of illness phase on
executive functioning performance using factor-derived cognitive scores
in a cross-sectional design.
Methods: Healthy control (HC) subjects (n = 57), and euthymic
(E-BD) (n = 117), depressed (D-BD) (n = 73), and hypomanic ⁄mixed
(HM ⁄M-BD) (n = 26) patients with bipolar disorder (BD) were
evaluated using executive functioning measures (Wisconsin Card Sorting
Test, Trail Making Test–Parts A and B, Verbal Fluency, Parametric
Go ⁄No-Go, Stroop, and Digit Symbol) comprising Conceptual
Reasoning and Set-Shifting (CRSS), Processing Speed with Interference
Resolution (PSIR), Verbal Fluency and Processing Speed (VFPS), and
Inhibitory Control (IC) factor scores.
Results: Two of the four executive functioning factors were significantly
different between groups based upon phase of illness. The HM ⁄M group
was significantly worse than both of the other BD groups and the HC
group in IC. The VFPS factor was sensitive to the active phase of BD, with
the HM ⁄M-BD and D-BD groups worse than HC. Extending our prior
work, the PSIR factor, and now the CRSS factor were significantly worse
in BD relative to HC, irrespective of phase of illness.
Conclusions: Phase of illness had differential cognitive profiles in
executive functioning factors, even after considering and excluding the
impact of clinical features, illness characteristics, medications, and
demographics. Consolidating executive functioning tasks into reliable
factor scores provides unique information to measure and define
cognitive deficiencies throughout phases of BD, and to measure
intermediate phenotypes in BD, and may aid in tracking and clarifying
treatment focus.
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the relative paucity of literature in this important
area. For example, a small study demonstrated that
remitted BD patients performed more accurately
than manic BD patients on tasks of inhibitory
control, response initiation ⁄ suppression, and ver-
bal fluency (3). Other cross-sectional studies have
found no differences when comparing remitted to
manic or hypomanic states (7, 12, 14, 15) or
remitted to depressed state (7, 12–15), but these
were similarly limited by small sample sizes, a
limited selection of EF measures, and failure to use
convergent data methods like factor analysis.
In other contexts, factor analysis has been used
to obtain reliable estimates of underlying cognitive
constructs, which minimizes measurement error (2,
16, 17). This technique provides a stronger
approach to measure and define cognitive abilities.
Consolidating EF tasks into relevant factor scores
is more likely to reflect the underlying latent
variables present and can provide a greater under-
standing of particular deficits in BD. In addition,
factors scores could be considered as intermediate
phenotypes for BD, useful for genetic studies in
BD. Cognitive dysfunction has been suggested to
be a possible intermediate phenotype in BD (1, 2),
with a recent meta-analysis underscoring the
importance of neuropsychological variables in
determining intermediate cognitive phenotypes in
BD (1). According to Gottesman and Gould (18), a
candidate intermediate phenotype should be asso-
ciated with the illness and should be state-depen-
dent, therefore manifesting in an affected
individual whether or not the illness is in the active
state. Furthermore, traditional neuropsychological
tests often simultaneously measure multiple aspects
of EF (19, 20) such as cognitive flexibility, set-
shifting, planning, abstract thinking, rule acquisi-
tion, and response initiation and inhibition. It is
also possible that use of factor scores may result in
a better representation of the cognitive features
present in phases of BD illness.
Aims of the study
The aims of the present study were to segregate
those EF processes related to trait risk for
BD—or intermediate phenotypes—from those
EF processes that are influenced specifically by
different acute phases of the illness. Likewise, it is
possible that those factors that represent interme-
diate phenotypes would exhibit an additional
degree of dysfunction in active phases of illness.
The factor scores that were used represent under-
lying cognitive constructs representative of dis-
tinct aspects of EF based upon our prior work
(2). We predicted that all BD patients would
perform more poorly than healthy controls on all
EF factors. Additionally, we predicted that those
individuals in the manic ⁄hypomanic ⁄mixed state
would demonstrate poorer inhibitory control rel-
ative to healthy controls and relative to those
individuals in the depressed and euthymic states.
Those in the depressed phase of BD are expected
to perform worse than other BD groups and
healthy controls on EF tasks that have a timed or
contain a processing speed component.
Materials and methods
Subjects
All participants were recruited into a longitudinal
study of BD with the goal of gathering pheno-
typic data and biological material for the Prech-
ter Bipolar Repository at the University of
Michigan (Ann Arbor, MI, USA). Participants
included in the study were 216 individuals with
confirmed BD (187 with bipolar I disorder and
29 with bipolar II disorder) and 57 healthy
controls (HC). One hundred and twenty-two of
these BD subjects were reported in our prior
study (2) and we have added an additional 94
participants with BD and 23 healthy controls for
the present study. Notably, the prior study had a
very small number of subjects in the hypo-
manic ⁄mixed group (n = 13), preventing well-
powered comparisons of the type conducted
herein. Recruitment of participants occurred
through advertisements on the web and in the
newspaper, an outpatient specialty psychiatric
clinic, and an inpatient psychiatric unit. All
participants underwent an evaluation using the
Diagnostic Interview for Genetic Studies (DIGS)
(21), neuropsychological testing, psychiatric
symptom questionnaires, Hamilton Depression
Rating–17 item version (HDRS-17) (22), and
Young Mania Rating Scale (YMRS) (23). A best
estimate process by at least three of the authors
was used to confirm diagnoses. Participants were
excluded if they had active substance use at the
time of the evaluation or neurological disease.
The HDRS-17 and YMRS were used to deter-
mine mood state at the time of administration of
the neuropsychological tests. Of the 216 BD
patients assessed, 117 were assessed when euthy-
mic (HDRS-17 < 8 and YMRS < 8), 73 when
depressed (HDRS-17 ‡ 8 and YMRS < 8), and
26 when manic, hypomanic or mixed
(YMARS ‡ 8) (see Table 1). The manic ⁄hypo-
manic (n = 18) and mixed (n = 8, also had
HDRS-17 > 8) groups were combined into one




A battery of neuropsychological tasks measuring
components of EF were administered: the Wiscon-
sin Card Sorting Test (24), the Stroop Color and
Word Test (25), the FAS verbal fluency task of the
Controlled Oral Word Association Test, and
Animal Fluency (26), Digit Symbol from the
Wechsler Adult Intelligence Scale-III (WAIS-III)
(27), the Trail Making Test–Parts A and B (28),
and the Parametric Go ⁄No-Go task (29). Standard
data reduction techniques (principal axis factor
analysis) were used to collapse the EF tasks with
oblique rotation and were used as the factor scores
for subsequent analyses. All scores with negative
scale properties were inverted; as a result, lower
factor scores reflect poorer performance. A confir-
matory factor analysis was computed with the
above variables, consistent with our prior study
(2). The four factors were Verbal Fluency and
Processing Speed (VFPS), Conceptual Reasoning
and Set-Shifting (CRSS), Processing Speed with
Interference Resolution (PSIR), and Inhibitory
Control (IC). Variables that load on the factors
and reliability of the factor scores (adjusted alpha)
are reported in Table 2, similar to our previous
report. In addition to the above tasks, the Vocab-
ulary subtest from the Wechsler Abbreviated Scale
of Intelligence was compared as a methodological
control for premorbid ability (30).










(n = 57) F p-value
Age, mean (SD) 38.19 (12.14) 40.32 (11.96) 38.76 (13.19) 35.52 (14.75) 1.47 0.22
Education,
mean (SD)
15.48 (2.07) 15.00 (2.35) 14.68 (2.16) 15.88 (2.43) 2.52 0.06




12.61 (2.79) 12.22 (2.95) 11.43 (2.45) 12.75 (3.07) 1.42 0.24
HRDS-17,
mean (SD)b
4.56 (3.18) 13.86 (3.33) 12.27 (6.63) 1.38 (1.87) 183.97 < 0.001
YMRS, mean (SD)c 1.59 (1.93) 2.21 (2.02) 12.44 (5.61) 0.26 (0.78) 168.11 < 0.001




3.03 (3.49) 3.56 (6.40) 3.20 (2.94) NA 0.15 0.86
History of
psychosis, (%)a
64.0 60.9 56.5 0.77
Average no.
episodes ⁄ years ill,
mean (SD)
4.56 (16.30) 8.30 (33.70) 4.74 (5.40) NA 0.58 0.56
Mania (age at onset),
mean (SD)
22.90 (17.84) 22.10 (13.09) 17.96 (11.37) NA 0.96 0.39
Mania (no. episodes),
mean (SD)d
7.01 (14.40) 6.28 (11.37) 24.28 (37.47) NA 10.67 < 0.001
Depression (age at onset),
mean (SD)
19.08 (10.13) 18.42 (10.32) 18.31 (9.98) NA 0.20 0.82
Depression (no. episodes),
mean (SD)e
16.66 (45.56) 33.84 (59.06) 40.88 (46.62) NA 3.93 0.02
Hypomania (age at onset),
mean (SD)
14.72 (14.15) 13.49 (12.03) 18.88 (12.36) NA 1.55 0.21
Hypomania (no. episodes),
mean (SD)d
13.88 (30.34) 19.64 (40.36) 52.52 (73.99) NA 12.68 < 0.001
BD = bipolar disorder; D-BD = depressed bipolar disorder; E-BD = euthymic bipolar disorder; HDRS-17 = Hamilton Depression Rating
Scale–17 item version; HC = healthy controls; HM ⁄ M-BD = hypomanic or mixed bipolar disorder; NA = not applicable; SD = standard
deviation; WASI = Wecshler Adult Scale of Intelligence; YMRS = Young Mania Rating Scale.
aChi-square test.
bHC < E-BD < HM ⁄ M-BD < D-BD.
cHM ⁄ M-BD > E-BD, D-BD > HC.
dHM ⁄ M-BD > E-BD, D-BD.
eHM ⁄ M-BD > E-BD.
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Clinical variables
Specific clinical data points were extracted from the
DIGS interview to study the relationships between
factor scores and clinical indices of severity. These
variables, listed in Table 1, include the historical
number of psychiatric hospitalizations, age at onset
of first episode, summation of number of depres-
sive and manic episodes, lifetime presence of
psychosis, chronicity of affective symptoms, years
since first episode, and mean number of episodes
per year the individual was ill (i.e., mean number of
manic and depressive divided by number of years
since first episode). These clinical variables were
chosen based upon prior literature demonstrating
that these factors have a potential impact upon
cognitive functioning. There were no significant
differences between BD groups and HC for age:
F(2,207) = 0.662, p = 0.517; education:
F(2,207) = 1.979, p = 0.141; or gender: v2 (2,
n = 211) = 1.38, p = 0.502. There were no sig-
nificant differences between BD groups for number
of hospitalizations, lifetime presence of psychosis,
number of episodes per year that the individual
was ill, or age of onset of depression, mania, or
hypomania (see Table 1).
Table 2. Main effects for executive functioning factor scores in bipolar disorder and healthy control participants
Factor analysis
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Inhibitory Controld F(3,269) = 3.31,
p = 0.02
HC > HM ⁄ M
Parametric
Go ⁄ No-Go




D = depressed; E = euthymic; HC = healthy controls; HM ⁄ M = hypomanic or mixed.
aAlpha r = 0.80.
bAlpha r = 0.79.





Our hypotheses of overall EF impairment in BD,
and of phase-specific effects in BD were both
assessed with a 4 * 4 multivariate analysis of
variance (MANOVA). The four groups were
healthy controls (HC), currently depressed bipolar
disorder (D-BD), euthymic bipolar disorder
(E-BD), and hypomanic or mixed (HM ⁄M-BD).
The four factors of EF used were derived by
principal axis confirmatory factor analysis and
oblique rotation. In addition, other multivariate
analyses were run to evaluate the contributions,
and potentially confounding influence of clinical,
medication, and demographic variables.
Individuals with BD were taking a range of
medications from a broad range of classes. To
address the impact of medications on factor scores
between our BD groups, we examined the influence
of medications in two ways. First, MANOVAs
were used with binary yes ⁄no response options for
each of the five categories of medication (antide-
pressant, mood stabilizer, antipsychotic, seda-
tive ⁄anxiolytic, and stimulant) as the independent
variables and the factor scores as the dependent
variables. Secondly, we adopted a protocol often
seen in the literature to assess total medication
load. Antidepressant, anxiolytic, mood stabilizer,
and antipsychotic medications were coded as
absent = 0, low = 1, or high = 2 based on pre-
viously employed methods to convert each medi-
cation to a standardized dose (31–33)
Antipsychotics were converted into chlorproma-
zine dose equivalents (34). Following Hassel et al.’s
(31) methodology we generated a composite
measure of total medication load by summing all
individual medication codes for each individual
medication within categories for each BD partic-
ipant. Analysis of variance was used to compare
the four groups on total medication loading.
Results
Comparison of EF factor scores by group
A MANOVA was computed with the four EF
factor scores as dependent variables and the four
groups as independent variables. Results showed
that there was a significant group effect,
F(12,804) = 3.05, p < 0.0001; the HC group out-
performed the E-BD on two of the four EF factors
(PSIR and CRSS), the D-BD on three out of the
four EF factors (PSIR, CRSS, and VFPS), and the
HM ⁄M-BD group on four out of the four EF
factors (PSIR, CRSS, VFPS, and IC) (Fig. 1). The
E-BD performed similarly to the D-BD group on
all factors while both groups outperformed the
HM ⁄M-BD group on IC. These differences are
shown in Table 2 (with factor score ⁄ reliability) and
illustrated in Figure 1. Although the sample sizes
for the hypomanic–manic (n = 18) and mixed
(n = 8) BD patients were small, there were no
significant differences between these two groups for
any of the factor scores in a follow-up, two group
by four factor MANOVA, F(4, 21) = 0.805,
p = 0.535. There were also no differences between
the two subgroups of the HM ⁄M-BD group on
demographic or clinical variables, suggesting that
these groups were appropriate to combine for




Fig. 1. Phase of illness by executive function factor score. Factor scores were re-adjusted based on healthy control values being set to
zero. aHealthy controls performed significantly better than all bipolar disorder groups. bHealthy controls performed significantly
better than active phase bipolar disorder groups. cHealthy controls performed better than the hypomanic ⁄mixed group. dThe
hypomanic ⁄mixed group performed significantly worse than the depressed and euthymic bipolar disorder groups.
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Clinical variables by phase of BD illness
There were no significant differences between BD
groups (E, D, and HM ⁄M) onMANOVA for most
clinical variables and illness severity, such as
number of inpatient psychiatric hospitalizations,
age of onset, number of years ill, chronicity of
psychosis, chronicity of affective symptoms, or
total number of depressive and manic episodes per
year ill (Table 1). The HM-M BD showed signi-
ficantly more lifetime manic and hypomanic
episodes than E-BD and D-BD, F(6,400) = 5.72,
p < 0.001.
We took steps to rule out this illness severity
(episodes) marker as a confound driving particular
effects in targeted post-hoc analyses as appropriate
(when the HM-M BD group was significantly
different from any other BD group). To verify
specific phase of illness effects, we matched sub-
groups of the E-BD, D-BD and HM ⁄M-BD
groups based on number of manic and hypomanic
episodes, and an additional post-hoc analysis
was conducted. MANOVA results continued to
show a significant group effect, F(12,573) = 3.29,
p = 0.0001; the HC group outperformed the
E-BD on three of the four EF factors (PSIR,
CRSS, and VFPS), the D-BD on three out of the
four EF factors (PSIR, CRSS, and VFPS), and the
HM ⁄M-BD group on three out of the four EF
factors (PSIR, CRSS, and IC). In this specific post-
hoc analysis, the E-BD performed similarly to the
D-BD group on all factors and the E-BD and
D-BD groups still outperformed the HM ⁄M-BD
group on IC (p < 0.05).
There were no significant differences between all
four groups on the vocabulary subtest of the
WASI, F(3) = 1.42, p = 0.238, a traditionally
defined ‘hold’ test that would be expected not to
change based upon scar or burden effects of illness
(35). The lack of difference on both the vocabulary
subtest and in years of formal education between
groups suggests that they were well matched in
premorbid ability.
Medication effects on EF factor scores in BD
The effects of medication may have confounded the
results of the study, as those in the active state of
illness or with more severe illness might be expected
to be prescribed more medications and there might
be variable adherence with medication by phase of
illness. Each medication effect on the four factor
scores was assessed in a MANCOVA ⁄MANOVA,
with binary yes ⁄no response options for each of the
five categories of medication (antidepressant, mood
stabilizer, antipsychotic, sedative ⁄anxiolytic, and
stimulant) used as the independent variables.
HDRS-17, YMRS, age of illness onset, number of
years ill, and number of inpatient psychiatric
hospitalizations were initially entered as covariates
in the model. For four out of the five classes of
medications, there were no significant covariate
effects on the four EF factors. Therefore, results
from MANOVAs only are reported. There were no
differences in EF factor performance among indi-
viduals taking the following classes of mediations:
mood stabilizer: F(4,202) = 0.91, p = 0.46; anti-
depressant: F(4,202) = 0.23, p = 0.92; seda-
tive ⁄anxiolytic: F(4,202) = 0.69, p = 0.62; or
stimulant: F(4,202) = 0.54, p = 0.71. The sole
significant medication effect upon the EF factors
was for treatment with antipsychotics, F(4,202) =
2.87, p = 0.02. Those taking this class of medica-
tions had worse performance on the VFPS factor,
F(1,205) = 9.87, p = 0.002; however, those taking
antipsychotic medications tend to have a history of
a greater number of inpatient hospitalizations,
suggesting that disease severity may have contrib-
uted to this EF performance difference, similar to
prior work (36). Among types of mood stabilizers,
lithium has been associated with cognitive side
effects, such as mental slowing. In this study, there
were no differences in performance in individuals
taking lithium compared to those taking some other
mood stabilizer, F(4,140) = 1.75, p = 0.14 for the
four factor scores.
Additionally, a correlational analysis was used
to examine the relationship between the four EF
factor scores and total medication loadings for all
BD participants. Total medication loading was not
correlated with the VFPS (r = )0.14, p = 0.17),
CRSS (r = )0.01, p = 0.89), PSIR (r = )0.11,
p = 0.26), or IC (r = )0.09, p = 0.39) factors.
There also were no differences in total medication
loading between the three BD groups, F(2) = 2.31,
p = 0.10.
Relationship of EF factor scores with clinical variables
Bivariate correlations between EF factor scores
and clinical variables for all BD patients as well as
just the E-BD group are shown in Table 3. These
are provided to better characterize the subgroups
of BD participants and for comparison with other
studies, not as additional, hypothesis-driven com-
parisons. Among all BD patients, number of
inpatient hospitalizations was negatively associated
with three out of the four factor scores (VFPS,
r = )0.26; CRSS, r = )0.37; and PSIR, r =
)0.20), number of years ill was significantly asso-
ciated with three factors scores (VFPS, r = )0.20;
CRSS, r = )0.23; and PSIR, r = )0.32), the
Ryan et al.
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HRDS was significantly associated with one factor
(VFPS, r = )0.14), and the YMRS was signifi-
cantly associated with one factor (IC, r = )0.15).
Number of hypomanic ⁄mixed episodes was signif-
icantly associated with two factors (CRSS,
r = )0.15; and PSIR, r = )0.16). Age of onset
of any mood episode was negatively associated
with PSIR (r = )0.17). None of the other clinical
variables were significantly related to the factor
scores (p > 0.05).
Discussion
Cognitive intermediate phenotypes for BD
There are general EF impairments observed in
active and euthymic phases of BD, as well as
specific EF impairments related to the two active
phases of BD evaluated here. All BD patients
performed worse than healthy controls on tasks of
PSIR and CRSS. This suggests that executive tasks
that comprise a set-shifting or interference resolu-
tion component are weaker among BD patients,
regardless of mood state, and are potentially strong
intermediate phenotypes in BD. There are addi-
tional, more modest effects based upon years of
illness, number of hospitalizations, and current
phase of illness above and beyond what could be
considered the intermediate phenotype component
for these set-shifting and interference resolution
factors. Nonetheless, there is sufficient evidence,
from our work and in the literature, that these are
intermediate phenotypes worthy of further, careful
investigation (1).
Furthermore, individuals in the remitted state
performed similarly to, often only slightly and non-
significantly better than, those who were currently
depressed or hypomanic ⁄mixed on factors assess-
ing VFPS, PSIR, and the conceptual reasoning
with set-shifting, suggesting that these deficiencies
may be chronic, trait-like deficiencies in BD. These
factor scores use combinations of the Wisconsin
Card Sorting Test, Trail Making Test, Stroop
Color Word Test, Digit Symbol, and Parametric
Go ⁄No-Go test, similar to findings in other studies
that showed worse performance in BD as com-
pared to healthy controls (1, 2). Furthermore, our
findings confirm and extend PSIR as a potential
intermediate phenotype. This factor was identified
as a potential marker in our previous work using a
smaller sample of our participants. Here we show
with greater specificity that three EF factors have
trait-like characteristics for intermediate pheno-
type consideration, beyond the one factor from the
previous study.















)0.26c ()0.35c) )0.37c ()0.39c) )0.20d ()0.24d) )0.03 ()0.02)
Age at onset 0.12 (0.06) 0.01 ()0.04) )0.17d ()0.22d) 0.03 (0.19d)
Total depressive
episodes
)0.06 (0.05) )0.10 (0.05) )0.10 (0.03) 0.05 (0.14)
Total hypomania ⁄
mixed episodesb
0.80 ()0.05) )0.15d ()0.10) )0.16d ()0.15) )0.13 (0.08)
Chronicity of
psychosis
)0.13 ()0.15) )0.05 ()0.06) )0.05 ()0.20) )0.01 (0.04)
Chronicity of
affective symptoms
0.02 (0.02) )0.04 ()0.04) )0.08 ()0.06) )0.06 ()0.14)
No. years of illness )0.20c ()0.09) )0.23c ()0.21d) )0.32c ()0.32c) 0.08 (0.03)
No. episodes ⁄ years ill )0.10 ()0.16) 0.07 (0.09) 0.002 ()0.04) )0.06 ()0.02)
Hamilton Depression
Rating Scale
)0.14d ()0.01) )0.01 (0.14) )0.07 ()0.08) )0.03 (0.01)
Young Mania
Rating Scale
0.01 ()0.13) 0.01 (0.06) )0.07 ()0.11) )0.15d ()0.11)
Total medication
load
)0.14 (0.17) )0.01 (0.89) )0.11 (0.26) )0.09 (0.39)
aThe values in parentheses are correlations between the clinical variables within the euthymic bipolar disorder group only.
bSample matched on no. hypomanic ⁄ mixed episodes.
cp < 0.01.
dp < 0.05.
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Non-specific executive dysfunction in both active phases
of BD
Patients in the two active mood states performed
similarly on most EF factors except for inhibitory
control. The factor where both active groups, but
not the remitted group, underperformed relative
to the healthy control group was the VFPS factor.
As seen in Figure 1, however, the relative magni-
tude of the difference between the remitted BD
group and the hypomanic ⁄mixed group or the
depressed group was relatively small. This sug-
gests that the VFPS factor may be a relatively
weak intermediate cognitive phenotype, with a
very modest trait-like effect, and more marked
phase effects.
Specific executive dysfunction for inhibitory control in the
hypomanic and mixed phase of BD
Individuals in the hypomanic ⁄mixed group had
worse inhibitory control as compared to the
depressed and euthymic patients, a novel and
well-powered finding within the context of groups
matched on clinical, demographic, premorbid and
treatment characteristics. This is consistent with
the notion that those in a hypomanic ⁄mixed state
have greater difficulties regulating behavior. One of
the key diagnostic features of the manic state is
difficulty with impulse control, and the present
findings confirm and specify the nature of this
relationship. These findings significantly extend
our prior pilot findings in which only the healthy
controls outperformed the hypomanic ⁄mixed
group on inhibitory control. In the present study,
those in the hypomanic ⁄mixed phase underper-
formed relative to matched depressed and euthy-
mic groups. These findings would appear similar to
those of the pilot study by Dixon et al. (4), who
reported that individuals in the manic phase
performed worse on inhibitory control than indi-
viduals in the remitted phase. The study of Dixon
and colleagues was confounded by significant
differences in education, premorbid ability, anti-
psychotic doses, degree of thought disorder by
phase of illness, and presence of mixed symptoms
in the depressed and manic samples, which made it
difficult to be confident about the results. In
contrast, the present study clarifies and extends
this pilot study with a larger group and adds
several important qualifiers. Here, we show phase-
specific impairments in the hypomania ⁄mixed
group for inhibitory control relative to the
depressed and euthymic groups. Our euthymic
and depressed groups have negligible manic symp-
toms, and the inhibitory control-specific results are
the same when groups are matched on all of the
clinical and demographic features of interest. In
addition, we show that it is a specific effect related
to inhibitory control, whereas other effects are
related to active phase of illness (VFPS), or
presence of illness (conceptual reasoning with set
shifting, and PSIR), more generally.
Treatment implications of inhibitory control dysfunction in
hypomanic ⁄ mixed states
The capacity to measure current levels of and
changes in EF performance can have important
clinical implications. First, EF changes may
coincide with or predate phase shifts in illness
and can aid in self- and clinician-identification
with subsequent treatment modification. For
example, it is possible that changes in inhibitory
control occur early in the hypomanic phase,
before full-blown mania has emerged. The in-
creased interpersonal, vocational, and legal ram-
ifications of the manic phase of illness might be
avoided with early identification and treatment
modification.
In addition, specific knowledge of intra-patient
fluctuation in EF can aid in redefining treatment
focus and disease management. A differential
pattern of executive dysfunction in a phase-specific
manner in BD suggests that multiple tests are
needed to fully characterize and understand EF.
Thus treatment uses for diagnostic purposes, such
as traditional clinical neuropsychological evalua-
tion, may need several EF tasks to be administered
to fully assess pertinent subdomains. In contrast,
to develop tools to track impulsivity, for example,
a much more limited subset could be used for
repeated assessment in clinical settings.
Limitations
One specific limitation for this study in comparing
groups by current phase of illness was the inclusion
of a relatively small hypomanic ⁄mixed group, in
comparison to the large euthymic BD and
depressed BD groups. Important effects for this
group in comparison to other groups may have
been missed. A larger hypomanic ⁄mixed BD group
should be recruited in order to demonstrate signif-
icant differences more clearly. Another important
limitation of the study is the cross-sectional design,
which prevents examination of intra-individual
differences in EF over time. It is difficult to
speculate whether the pattern of executive dys-
function by phase of BD illness will change as
individuals shift from one phase to another phase.
Future studies could investigate this by using a
Ryan et al.
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longitudinal design, a specific aim of the Prechter
Longitudinal Study of BD. As is common among
most naturalistic studies of this kind, it is difficult
to control for the effects of medication, treatment
adherence, and treatment optimization. However,
we did not show substantial adverse effects of most
medication classes, with the exception that those
being treated with antipsychotic medications
performed more poorly than those not taking
antipsychotic medications. When using a protocol
often seen in the literature to assess total medica-
tion load in patients with BD, we found no
difference between our three BD groups based
upon medication load, and medication load was
not related to the EF factor scores.
Conclusion
Prior studies of EF in BD have primarily focused
on comparing individuals in one or two phases of
the BD illness to healthy controls or have focused
on only comparing depressed to euthymic, manic to
euthymic, or manic to depressed using very small
sample sizes and poorly represented BD groups. A
particular strength of the present study was the
inclusion of a well-representative, well-character-
ized, and large sample of BD individuals and a large
healthy comparison group. In summary, EF factors
appear to have promise as intermediate cognitive
phenotypes marking trait risk for illness in the
PSIR and CRSS factors. In addition, there are two
factors that are moderated by phase of illness.
Specifically, VFPS appears to worsen in the
depressed and hypomanic ⁄mixed phase of illness.
In contrast, IC worsens in the manic phase of illness
with similar performance on the factor between the
depressed and remitted patients. These factor
scores may aid in tracking EF across phase of BD
illness, which may one day be objectively helpful in
tracking a patient’s risk for mania.
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